142 related articles for article (PubMed ID: 20625418)
1. Matrix metalloproteinase-2 promoter genotype as a marker of cutaneous T-cell lymphoma early stage.
Vasku A; Vasku JB; Necas M; Vasku V
J Biomed Biotechnol; 2010; 2010():805907. PubMed ID: 20625418
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase-2 promoter variability in psoriasis.
Vasku V; Bienertova Vasku J; Slonková V; Kanková K; Vasku A
Arch Dermatol Res; 2009 Jul; 301(6):467-73. PubMed ID: 19360430
[TBL] [Abstract][Full Text] [Related]
3. A haplotype constituted of four MMP-2 promoter polymorphisms (-1575G/A, -1306C/T, -790T/G and -735C/T) is associated with coronary triple-vessel disease.
Vasků A; Goldbergová M; Izakovicová Hollá L; Sisková L; Groch L; Beránek M; Tschöplová S; Znojil V; Vácha J
Matrix Biol; 2004 Jan; 22(7):585-91. PubMed ID: 14996438
[TBL] [Abstract][Full Text] [Related]
4. New Genetic Markers of Skin T-Cell Lymphoma Treatment.
Vašků V; Fialová P; Vašků A
Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540417
[TBL] [Abstract][Full Text] [Related]
5. Parapsoriasis en plaques: its potential for progression to malignant lymphoma.
Kikuchi A; Naka W; Harada T; Sakuraoka K; Harada R; Nishikawa T
J Am Acad Dermatol; 1993 Sep; 29(3):419-22. PubMed ID: 8394392
[TBL] [Abstract][Full Text] [Related]
6. Telomerase activity and telomere length in lymphocytes from patients with cutaneous T-cell lymphoma.
Wu K; Lund M; Bang K; Thestrup-Pedersen K
Cancer; 1999 Sep; 86(6):1056-63. PubMed ID: 10491534
[TBL] [Abstract][Full Text] [Related]
7. High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.
Valencak J; Schmid K; Trautinger F; Wallnöfer W; Muellauer L; Soleiman A; Knobler R; Haitel A; Pehamberger H; Raderer M
J Dermatol Sci; 2011 Dec; 64(3):185-90. PubMed ID: 21937200
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
9. Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome.
Shin J; Monti S; Aires DJ; Duvic M; Golub T; Jones DA; Kupper TS
Blood; 2007 Oct; 110(8):3015-27. PubMed ID: 17638852
[TBL] [Abstract][Full Text] [Related]
10. Heterozygote AG variant of -596 A/G IL-6 gene polymorphism is a marker for cutaneous T-cell lymphoma (CTCL).
Vasku JA; Vasku A; Goldbergova M; Vasku V
Clin Immunol; 2004 Dec; 113(3):256-60. PubMed ID: 15507390
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase-2 promoter and tissue inhibitor of metalloproteinase-2 gene polymorphisms in non-Hodgkin's lymphoma.
Diao LP; Ma H; Wei GC; Li T; Liu HS; Liu LH; Wu LL; Zhao GM; Gao YH
Int J Cancer; 2012 Sep; 131(5):1095-103. PubMed ID: 22020421
[TBL] [Abstract][Full Text] [Related]
12. ALK-positive primary cutaneous T-cell-lymphoma (CTCL) with unusual clinical presentation and aggressive course.
Wehkamp U; Oschlies I; Nagel I; Brasch J; Kneba M; Günther A; Klapper W; Weichenthal M
J Cutan Pathol; 2015 Nov; 42(11):870-7. PubMed ID: 26053561
[TBL] [Abstract][Full Text] [Related]
13. Genetic variations in the human gelatinase A (matrix metalloproteinase-2) promoter are not associated with susceptibility to, and severity of, chronic periodontitis.
Holla LI; Fassmann A; Vasku A; Goldbergova M; Beranek M; Znojil V; Vanek J; Vacha J
J Periodontol; 2005 Jul; 76(7):1056-60. PubMed ID: 16018746
[TBL] [Abstract][Full Text] [Related]
14. Association between matrix metalloproteinase 2 (MMP2) promoter polymorphisms and the susceptibility to non-Hodgkin's lymphoma in Egyptians.
Gouda HM; Khorshied MM; El Sissy MH; Shaheen IA; Mohsen MM
Ann Hematol; 2014 Aug; 93(8):1313-8. PubMed ID: 24627195
[TBL] [Abstract][Full Text] [Related]
15. Expression of Granulysin and FOXP3 in Cutaneous T Cell Lymphoma and Sézary Syndrome.
Shareef MM; Elgarhy LH; Wasfy Rel-S
Asian Pac J Cancer Prev; 2015; 16(13):5359-64. PubMed ID: 26225678
[TBL] [Abstract][Full Text] [Related]
16. Chromosomal abnormalities in relation to clinical disease in patients with cutaneous T-cell lymphoma: a 5-year follow-up study.
Karenko L; Sarna S; Kähkönen M; Ranki A
Br J Dermatol; 2003 Jan; 148(1):55-64. PubMed ID: 12534595
[TBL] [Abstract][Full Text] [Related]
17. T-cell receptor gene rearrangement analysis: cutaneous T cell lymphoma, peripheral T cell lymphoma, and premalignant and benign cutaneous lymphoproliferative disorders.
Zelickson BD; Peters MS; Muller SA; Thibodeau SN; Lust JA; Quam LM; Pittelkow MR
J Am Acad Dermatol; 1991 Nov; 25(5 Pt 1):787-96. PubMed ID: 1839392
[TBL] [Abstract][Full Text] [Related]
18. The polymorphisms of IL-6/STAT3 signaling pathway may contribute to cutaneous T-cell lymphomas susceptibility.
Olszewska B; Gleń J; Zabłotna M; Nowicki RJ; Sokołowska-Wojdyło M
Arch Dermatol Res; 2021 Jan; 313(1):25-31. PubMed ID: 32270320
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73.
van Doorn R; Zoutman WH; Dijkman R; de Menezes RX; Commandeur S; Mulder AA; van der Velden PA; Vermeer MH; Willemze R; Yan PS; Huang TH; Tensen CP
J Clin Oncol; 2005 Jun; 23(17):3886-96. PubMed ID: 15897551
[TBL] [Abstract][Full Text] [Related]
20. Role of high-throughput sequencing in the diagnosis of cutaneous T-cell lymphoma.
Rea B; Haun P; Emerson R; Vignali M; Farooqi M; Samimi S; Elenitsas R; Kirsch I; Bagg A
J Clin Pathol; 2018 Sep; 71(9):814-820. PubMed ID: 29636372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
